Rhythm Pharmaceuticals (NASDAQ:RYTM) Given New $166.00 Price Target at Citizens Jmp

Posted by Francis Steltz on Nov 5th, 2026

Rhythm Pharmaceuticals (NASDAQ:RYTM – Free Report) had its price objective upped by Citizens Jmp from $160.00 to $166.00 in a report published on Wednesday,Benzinga reports. The brokerage currently has a market outperform rating on the stock.

A number of other analysts also recently issued reports on the company. Needham & Company LLC decreased their target price on Rhythm Pharmaceuticals from $130.00 to $114.00 and set a “buy” rating for the company in a research report on Tuesday. William Blair assumed coverage on Rhythm Pharmaceuticals in a research report on Friday, October 16th. They set an “outperform” rating on the stock. National Bank Financial set a $160.00 price target on Rhythm Pharmaceuticals in a research note on Wednesday, August 5th. Oppenheimer reissued a “market perform” rating on shares of Rhythm Pharmaceuticals in a report on Wednesday. Finally, HC Wainwright increased their price objective on Rhythm Pharmaceuticals from $105.00 to $130.00 and gave the stock a “buy” rating in a report on Monday, October 12th. Eighteen research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $141.94.

View Our Latest Analysis on RYTM

Rhythm Pharmaceuticals Price Performance

RYTM opened at $110.68 on Wednesday. Rhythm Pharmaceuticals has a fifty-two week low of $74.50 and a fifty-two week high of $122.20. The company’s 50-day moving average is $96.29 and its 200 day moving average is $97.18. The firm has a market capitalization of $7.59 billion, a P/E ratio of -38.17 and a beta of 2.17.

Rhythm Pharmaceuticals (NASDAQ:RYTM – Get Free Report) last posted its quarterly earnings results on Tuesday, November 3rd. The company reported ($0.61) earnings per share for the quarter, beating the consensus estimate of ($0.71) by $0.10. Rhythm Pharmaceuticals had a negative net margin of 69.03% and a negative return on equity of 159.32%. The company had revenue of $92.13 million during the quarter, compared to analyst estimates of $85.56 million. During the same quarter in the prior year, the business earned ($0.82) earnings per share. The firm’s revenue for the quarter was up 79.6% on a year-over-year basis. On average, equities research analysts expect that Rhythm Pharmaceuticals will post -2.77 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO David P. Meeker sold 50,000 shares of the business’s stock in a transaction on Monday, September 14th. The shares were sold at an average price of $102.67, for a total transaction of $5,133,500.00. Following the sale, the chief executive officer owned 239,258 shares in the company, valued at approximately $24,564,618.86. The trade was a 17.29% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Alastair Garfield sold 7,763 shares of the stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $117.57, for a total transaction of $912,695.91. Following the completion of the transaction, the insider owned 2,295 shares of the company’s stock, valued at approximately $269,823.15. The trade was a 77.18% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 258,450 shares of company stock valued at $28,796,497 in the last 90 days. Corporate insiders own 5.90% of the company’s stock.

Hedge Funds Weigh In On Rhythm Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. GAMMA Investing LLC raised its stake in Rhythm Pharmaceuticals by 36.3% during the second quarter. GAMMA Investing LLC now owns 364 shares of the company’s stock valued at $40,000 after buying an additional 97 shares during the last quarter. EverSource Wealth Advisors LLC grew its stake in shares of Rhythm Pharmaceuticals by 106.4% in the first quarter. EverSource Wealth Advisors LLC now owns 549 shares of the company’s stock worth $48,000 after acquiring an additional 283 shares during the last quarter. Global Retirement Partners LLC purchased a new stake in shares of Rhythm Pharmaceuticals in the second quarter worth $51,000. Pinnacle Wealth Planning Services Inc. increased its holdings in shares of Rhythm Pharmaceuticals by 894.0% during the third quarter. Pinnacle Wealth Planning Services Inc. now owns 666 shares of the company’s stock valued at $63,000 after acquiring an additional 599 shares in the last quarter. Finally, Nisa Investment Advisors LLC increased its holdings in shares of Rhythm Pharmaceuticals by 9.1% during the third quarter. Nisa Investment Advisors LLC now owns 1,630 shares of the company’s stock valued at $155,000 after acquiring an additional 136 shares in the last quarter.

Key Stories Impacting Rhythm Pharmaceuticals

Here are the key news stories impacting Rhythm Pharmaceuticals this week:

Positive Sentiment: Reported acquisition offer: The Wall Street Journal and Reuters reported that AstraZeneca recently offered about $10 billion for Rhythm, potentially giving investors a substantial takeover catalyst. Reuters report Wall Street Journal article
Positive Sentiment: Expanded coverage potential: NICE issued positive guidance expanding IMCIVREE coverage in England to include adults with genetically confirmed Bardet-Biedl syndrome, potentially widening access to the treatment. Company announcement
Positive Sentiment: Quarterly results beat expectations: Third-quarter revenue was $92.1 million, up 79.6% year over year and ahead of estimates; the $0.61-per-share loss was also narrower than expected. Quarterly results
Neutral Sentiment: Pipeline funding and revised license terms: Rhythm secured up to $750 million in financing and reduced LG Chem’s royalty rate to 1%, while committing to $350 million in fixed payments over four years. The arrangement supports development but includes significant future payments. License amendment
Negative Sentiment: Recent earnings-related volatility: Rhythm’s shares reportedly fell after its quarterly report, and Needham lowered its price target to $114 despite maintaining a Buy rating. The takeover report has since become the more prominent catalyst. Earnings reaction

Rhythm Pharmaceuticals Company Profile

(Get Free Report)

Rhythm Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare genetic diseases of obesity and related metabolic disorders. The company’s work is based on the melanocortin-4 receptor (MC4R) pathway, which plays an important role in regulating hunger and energy balance.

Rhythm’s principal product is IMCIVREE (setmelanotide), a targeted therapy designed to restore impaired MC4R pathway signaling. In the United States, IMCIVREE is approved for chronic weight management in adults and children at least 6 years old with obesity caused by certain genetic deficiencies, including POMC, PCSK1, or LEPR deficiency, as well as Bardet-Biedl syndrome.